ANIP News and Press, ANI Pharmaceuticals Inc. From 02/27/20

ANI Pharmaceuticals (NASDAQ: ANIP ): Q4 Non-GAAP EPS of $1.08 misses by $0.10 ; GAAP EPS of -$0.41 misses by $0.56 . More news on: ANI Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

BAUDETTE, Minn. , Feb. 27, 2020 /PRNewswire/ -- For the full year ended December 31, 2019 : Record net revenues of $206.5 million , an increase of 2.5% versus 2018 GAAP net income of $6.1 million and diluted GAAP earnings per share of $0.50 Adjusted non-GAAP EBITDA o...

BAUDETTE, Minn. , Feb. 20, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its fourth quarter and year-to-date 2019 financial results on Thursday, February 27, 2020 , before the opening of the U.S. financial markets. Th...

BAUDETTE, Minn. , Feb. 12, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL. The current annual market for this product is approximately $29 million , ...

Corticotropin Gel Recommercialization Strategy In December 2015, ANI Pharmaceuticals ( ANIP ) acquired Cortropin Gel Injection (NDA #008975), 40 units/mL and 80 units/mL and for Cortropin-Zinc Injection (NDA #009854), 40 units/mL from Merck and Co. Inc. ( MRK ), for $75 million and a percent...

BlackRock Inc. ( BLK ) and Vanguard Group Inc. represent the world’s two largest Asset Management Companies. According to 2019 Q3 filing, BlackRock had $6.96 trillion USD in assets under management. While, according Vanguard , they had $5.6 trillion USD assets under management on Augus...

BAUDETTE, Minn. , Jan. 24, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Tolterodine Extended-Release Capsules, 2 mg and 4 mg.   The current annual U.S. market for this product is approximately $101 million , according to IQ...

BAUDETTE, Minn. , Jan. 16, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) for Potassium Citrate Extended-Release T...

BAUDETTE, Minn. , Jan. 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million , accordin...

BAUDETTE, Minn. , Jan. 9, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the acquisition of the U.S. portfolio of 23 generic products from Amerigen Pharmaceuticals, Ltd. for $52.5M in cash at close and up to $25M in contingent profit share p...